Effect of Combined Systemic and Local Morpholino Treatment on the Spinal Muscular Atrophy Δ7 Mouse Model Phenotype

Nizzardo, Monica; Simone, Chiara; Salani, Sabrina; Ruepp, Marc-David; Rizzo, Federica; Ruggieri, Margherita; Zanetta, Chiara; Brajkovic, Simona; Moulton, Hong M.; Mühlemann, Oliver; Bresolin, Nereo; Comi, Giacomo P.; Corti, Stefania (2014). Effect of Combined Systemic and Local Morpholino Treatment on the Spinal Muscular Atrophy Δ7 Mouse Model Phenotype. Clinical therapeutics, 36(3), 340-356.e5. Elsevier 10.1016/j.clinthera.2014.02.004

[img] Text
Nizzardo_Clinical Therapeutics 2014.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (3MB) | Request a copy
[img] Text
Manuscript%20Nizzardo%2016-1-14[1] with Figures.docx - Accepted Version
Available under License Publisher holds Copyright.

Download (1MB)

BACKGROUND: Spinal muscular atrophy (SMA) is a fatal motor neuron disease of childhood that is caused by mutations in the SMN1 gene. Currently, no effective treatment is available. One possible therapeutic approach is the use of antisense oligos (ASOs) to redirect the splicing of the paralogous gene SMN2, thus increasing functional SMN protein production. Various ASOs with different chemical properties are suitable for these applications, including a morpholino oligomer (MO) variant with a particularly excellent safety and efficacy profile. OBJECTIVE: We investigated a 25-nt MO sequence targeting the negative intronic splicing silencer (ISS-N1) 10 to 34 region. METHODS: We administered a 25-nt MO sequence against the ISS-N1 region of SMN2 (HSMN2Ex7D[-10-34]) in the SMAΔ7 mouse model and evaluated the effect and neuropathologic phenotype. We tested different concentrations (from 2 to 24 nM) and delivery protocols (intracerebroventricular injection, systemic injection, or both). We evaluated the treatment efficacy regarding SMN levels, survival, neuromuscular phenotype, and neuropathologic features. RESULTS: We found that a 25-nt MO sequence against the ISS-N1 region of SMN2 (HSMN2Ex7D[-10-34]) exhibited superior efficacy in transgenic SMAΔ7 mice compared with previously described sequences. In our experiments, the combination of local and systemic administration of MO (bare or conjugated to octaguanidine) was the most effective approach for increasing full-length SMN expression, leading to robust improvement in neuropathologic features and survival. Moreover, we found that several small nuclear RNAs were deregulated in SMA mice and that their levels were restored by MO treatment. CONCLUSION: These results indicate that MO-mediated SMA therapy is efficacious and can result in phenotypic rescue, providing important insights for further development of ASO-based therapeutic strategies in SMA patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

08 Faculty of Science > Departement of Chemistry and Biochemistry

UniBE Contributor:

Ruepp, Marc-David and Mühlemann, Oliver

Subjects:

500 Science > 570 Life sciences; biology
500 Science > 540 Chemistry

ISSN:

0149-2918

Publisher:

Elsevier

Language:

English

Submitter:

Christina Schüpbach

Date Deposited:

26 Mar 2015 08:53

Last Modified:

13 Sep 2017 06:42

Publisher DOI:

10.1016/j.clinthera.2014.02.004

BORIS DOI:

10.7892/boris.65846

URI:

https://boris.unibe.ch/id/eprint/65846

Actions (login required)

Edit item Edit item
Provide Feedback